Primary-source record
Decision-gradeTopline results
Invivyd VYD2311 DECLARATION Phase 3 topline data expected Q3 2026
DECLARATION pivotal trial enrollment is now complete with top-line data planned later in Q3 2026 to support potential BLA submission. LIBERTY Phase 3 trial is also fully dosed with top-line data anticipated in late Q3 2026.
Key facts
- Filed
- Aug 13, 2026, 08:11 PM
- Event
- Topline results
- Direction
- Neutral
- Company
IVVDInvivyd- Asset
- pemivibart
- Source
- SEC 8-K
- Confidence
- Sourced
Source excerpt
EX-99.1 2 ivvd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollment in VYD2311 DECLARATION clinical trial expansion cohort and LIBERTY clinical trial, driven by strong subject demand • DECLARATION pivotal clinical trial enrollment is complete; the ongoing study is approaching its planned analysis, and in lieu of a Q2 2026 quarterly earnings call, Invivyd plans to hold an investor call post study completion • LIBERTY study fully dosed with top-line data anticipated in late Q3 2026 • Strong balance sheet with Q2 2026 ending cash and cash equivalents of $160.1 million anticipated to provide runway through DECLARATION pivotal data readout and support potential commercial launch readiness for VYD2311 NEW HAVEN, Conn., August 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights. “With our VYD2311 DECLARATION and LIBERTY clinical trials planned to wrap up in the coming weeks, we are looking forward to the next steps for vulnerable Americans,” said Marc Elia, Chairman of the Board of Invivyd. “The public health need for antibody-based protection with attractive safety is enormous, and we are confident that many